Werutsky, G., Maluf, F. C., Cronemberger, E. H., Carrera Souza, V., dos Santos Martins, S. P., Peixoto, F., . . . Fay, A. (2019). The LACOG-0415 phase II trial: Abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer.
Styl ChicagoWerutsky, Gustavo, et al. "The LACOG-0415 Phase II Trial: Abiraterone Acetate and ADT Versus Apalutamide Versus Abiraterone Acetate and Apalutamide in Patients With Advanced Prostate Cancer With Non-castration Testosterone Levels." BMC Cancer 2019.
Citace podle MLAWerutsky, Gustavo, et al. "The LACOG-0415 Phase II Trial: Abiraterone Acetate and ADT Versus Apalutamide Versus Abiraterone Acetate and Apalutamide in Patients With Advanced Prostate Cancer With Non-castration Testosterone Levels." BMC Cancer 2019.